{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T03:33:23Z","timestamp":1767152003513,"version":"build-2238731810"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,8,18]],"date-time":"2016-08-18T00:00:00Z","timestamp":1471478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"},{"start":{"date-parts":[[2016,8,18]],"date-time":"2016-08-18T00:00:00Z","timestamp":1471478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2016,9,6]]},"DOI":"10.1038\/bjc.2016.247","type":"journal-article","created":{"date-parts":[[2016,8,18]],"date-time":"2016-08-18T18:51:37Z","timestamp":1471546297000},"page":"725-730","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia"],"prefix":"10.1038","volume":"115","author":[{"given":"Anne","family":"\u00d8rbo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marit","family":"Arnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena Myreng","family":"Lys\u00e5","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christer","family":"Borgfelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f8rn","family":"Straume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,18]]},"reference":[{"issue":"4","key":"BFbjc2016247_CR1","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ajog.2015.03.037","volume":"213","author":"HH Abu","year":"2015","unstructured":"Abu HH, Ghayaty E, El RM (2015) Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials. Am J Obstet Gynecol 213 (4): 469\u2013478.","journal-title":"Am J Obstet Gynecol"},{"key":"BFbjc2016247_CR2","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/j.1525-1438.2006.00533.x","volume":"16","author":"T Bese","year":"2006","unstructured":"Bese T, Vural A, Ozturk M, Dagistanli F, Demirkiran F, Tuncdemir M, Arvas M, Sanioglu C, Kosebay D (2006) The effect of long-term use of progesterone therapy on proliferation and apoptosis in simple endometrial hyperplasia without atypia. Int J Gynecol Cancer 16: 809\u2013813.","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"BFbjc2016247_CR3","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/bjc.2011.109","volume":"104","author":"E Bignotti","year":"2011","unstructured":"Bignotti E, Ragnoli M, Zanotti L, Calza S, Falchetti M, Lonardi S, Bergamelli S, Bandiera E, Tassi RA, Romani C, Todeschini P, Odicino FE, Facchetti F, Pecorelli S, Ravaggi A (2011) Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br J Cancer 104 (9): 1418\u20131425.","journal-title":"Br J Cancer"},{"key":"BFbjc2016247_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S1470-2045(06)70579-4","volume":"7","author":"D Bouchard","year":"2006","unstructured":"Bouchard D, Morisset D, Bourbonnais Y, Tremblay GM (2006) Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol 7: 167\u2013174.","journal-title":"Lancet Oncol"},{"key":"BFbjc2016247_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12885-015-1028-0","volume":"15","author":"DJ Brennan","year":"2015","unstructured":"Brennan DJ, Hackethal A, Mann KP, Mutz-Dehbalaie I, Fiegl H, Marth C, Obermair A (2015) Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance. BMC Cancer 15: 33\u20131028.","journal-title":"BMC Cancer"},{"key":"BFbjc2016247_CR6","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/j.1479-828X.2009.00981.x","volume":"49","author":"MJ Buttini","year":"2009","unstructured":"Buttini MJ, Jordan SJ, Webb PM (2009) The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia: an Australian study and systematic review. Aust N Z J Obstet Gynaecol 49: 316\u2013322.","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"BFbjc2016247_CR7","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1210\/me.2004-0274","volume":"19","author":"B Chen","year":"2005","unstructured":"Chen B, Pan H, Zhu L, Deng Y, Pollard JW (2005) Progesterone inhibits the estrogen-induced phosphoinositide 3-kinase\u2014&gt;AKT\u2014&gt;GSK-3beta\u2014&gt;cyclin D1\u2014&gt;pRB pathway to block uterine epithelial cell proliferation. Mol Endocrinol 19: 1978\u20131990.","journal-title":"Mol Endocrinol"},{"key":"BFbjc2016247_CR8","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ejogrb.2005.09.004","volume":"125","author":"TJ Clark","year":"2006","unstructured":"Clark TJ, Neelakantan D, Gupta JK (2006) The management of endometrial hyperplasia: an evaluation of current practice. Eur J Obstet Gynecol Reprod Biol 125: 259\u2013264.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"BFbjc2016247_CR9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13046-015-0208-8","volume":"34","author":"L Deng","year":"2015","unstructured":"Deng L, Gao Y, Li X, Cai M, Wang H, Zhuang H, Tan M, Liu S, Hao Y, Lin B (2015) Expression and clinical significance of annexin A2 and human epididymis protein 4 in endometrial carcinoma. J Exp Clin Cancer Res 34: 96\u20130208.","journal-title":"J Exp Clin Cancer Res"},{"key":"BFbjc2016247_CR10","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-04-3924","volume":"65","author":"R Drapkin","year":"2005","unstructured":"Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, Hecht JL (2005) Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 65: 2162\u20132169.","journal-title":"Cancer Res"},{"key":"BFbjc2016247_CR11","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/0002-9378(89)90103-8","volume":"160","author":"A Ferenczy","year":"1989","unstructured":"Ferenczy A, Gelfand M (1989) The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol 160: 126\u2013131.","journal-title":"Am J Obstet Gynecol"},{"key":"BFbjc2016247_CR12","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1093\/humrep\/det320","volume":"28","author":"ID Gallos","year":"2013","unstructured":"Gallos ID, Krishan P, Shehmar M, Ganesan R, Gupta JK (2013a) LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study. Hum Reprod 28: 2966\u20132971.","journal-title":"Hum Reprod"},{"key":"BFbjc2016247_CR13","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/humrep\/det049","volume":"28","author":"ID Gallos","year":"2013","unstructured":"Gallos ID, Krishan P, Shehmar M, Ganesan R, Gupta JK (2013b) Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up. Hum Reprod 28: 1231\u20131236.","journal-title":"Hum Reprod"},{"key":"BFbjc2016247_CR14","doi-asserted-by":"publisher","first-page":"547.e1","DOI":"10.1016\/j.ajog.2010.07.037","volume":"203","author":"ID Gallos","year":"2010","unstructured":"Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK (2010) Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 203: 547.e1\u201310.","journal-title":"Am J Obstet Gynecol"},{"key":"BFbjc2016247_CR15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/j.1349-7006.2010.01829.x","volume":"102","author":"C Gu","year":"2011","unstructured":"Gu C, Zhang Z, Yu Y, Liu Y, Zhao F, Yin L, Feng Y, Chen X (2011) Inhibiting the PI3K\/Akt pathway reversed progestin resistance in endometrial cancer. Cancer Sci 102: 557\u2013564.","journal-title":"Cancer Sci"},{"key":"BFbjc2016247_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/(SICI)1096-9896(199610)180:2<223::AID-PATH635>3.0.CO;2-H","volume":"180","author":"A Huang","year":"1996","unstructured":"Huang A, Pettigrew NM, Watson PH (1996) Immunohistochemical assay for oestrogen receptors in paraffin wax sections of breast carcinoma using a new monoclonal antibody. J Pathol 180: 223\u2013227.","journal-title":"J Pathol"},{"key":"BFbjc2016247_CR17","doi-asserted-by":"publisher","first-page":"22655","DOI":"10.3390\/ijms141122655","volume":"14","author":"SW Jiang","year":"2013","unstructured":"Jiang SW, Chen H, Dowdy S, Fu A, Attewell J, Kalogera E, Drapkin R, Podratz K, Broaddus R, Li J (2013) HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival. Int J Mol Sci 14: 22655\u201322677.","journal-title":"Int J Mol Sci"},{"key":"BFbjc2016247_CR18","first-page":"365","volume":"22","author":"T Jobo","year":"2001","unstructured":"Jobo T, Kawaguchi M, Imai M, Kuramoto H (2001) Treatment for complex atypical hyperplasia of the endometrium. Eur J Gynaecol Oncol 22: 365\u2013368.","journal-title":"Eur J Gynaecol Oncol"},{"key":"BFbjc2016247_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1757-2215-5-20","volume":"5","author":"G Kalapotharakos","year":"2012","unstructured":"Kalapotharakos G, Asciutto C, Henic E, Casslen B, Borgfeldt C (2012) High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer. J Ovarian Res 5: 20\u201325.","journal-title":"J Ovarian Res"},{"key":"BFbjc2016247_CR20","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/1097-0142(19850715)56:2<403::AID-CNCR2820560233>3.0.CO;2-X","volume":"56","author":"RJ Kurman","year":"1985","unstructured":"Kurman RJ, Kaminski PF, Norris HJ (1985) The behavior of endometrial hyperplasia. A long-term study of \"untreated\" hyperplasia in 170 patients. Cancer 56: 403\u2013412.","journal-title":"Cancer"},{"key":"BFbjc2016247_CR21","first-page":"437468","volume":"2015","author":"X Li","year":"2015","unstructured":"Li X, Gao Y, Tan M, Zhuang H, Gao J, Hu Z, Wang H, Zhu L, Liu J, Lin B (2015) Expression of HE4 in endometrial cancer and its clinical significance. Biomed Res Int 2015: 437468.","journal-title":"Biomed Res Int"},{"key":"BFbjc2016247_CR22","first-page":"1239","volume":"8","author":"X Liu","year":"2015","unstructured":"Liu X, Zhao F, Hu L, Sun Y (2015) Value of detection of serum human epididymis secretory protein 4 and carbohydrate antigen 125 in diagnosis of early endometrial cancer of different pathological subtypes. Onco Targets Ther 8: 1239\u20131243.","journal-title":"Onco Targets Ther"},{"issue":"2","key":"BFbjc2016247_CR23","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.bbrc.2012.02.008","volume":"419","author":"R Lu","year":"2012","unstructured":"Lu R, Sun X, Xiao R, Zhou L, Gao X, Guo L (2012) Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility. Biochem Biophys Res Commun 419 (2): 274\u2013280.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFbjc2016247_CR24","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.canlet.2006.06.013","volume":"248","author":"T Minaguchi","year":"2007","unstructured":"Minaguchi T, Nakagawa S, Takazawa Y, Nei T, Horie K, Fujiwara T, Osuga Y, Yasugi T, Kugu K, Yano T, Yoshikawa H, Taketani Y (2007) Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium. Cancer Lett 248: 112\u2013122.","journal-title":"Cancer Lett"},{"key":"BFbjc2016247_CR25","first-page":"1053","volume":"29","author":"BG Moe","year":"2009","unstructured":"Moe BG, Vereide AB, Orbo A, Sager G (2009a) High concentrations of progesterone and mifepristone mutually reinforce cell cycle retardation and induction of apoptosis. Anticancer Res 29: 1053\u20131058.","journal-title":"Anticancer Res"},{"key":"BFbjc2016247_CR26","first-page":"1047","volume":"29","author":"BT Moe","year":"2009","unstructured":"Moe BT, Vereide AB, Orbo A, Jaeger R, Sager G (2009b) Levonorgestrel, medroxyprogesterone and progesterone cause a concentration-dependent reduction in endometrial cancer (Ishikawa) cell density, and high concentrations of progesterone and mifepristone act in synergy. Anticancer Res 29: 1047\u20131052.","journal-title":"Anticancer Res"},{"issue":"2","key":"BFbjc2016247_CR27","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ygyno.2008.04.002","volume":"110","author":"RG Moore","year":"2008","unstructured":"Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, Granai CO, Bast RC Jr . Lu K (2008) Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol 110 (2): 196\u2013201.","journal-title":"Gynecol Oncol"},{"key":"BFbjc2016247_CR28","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/AOG.0b013e318224fce2","volume":"118","author":"RG Moore","year":"2011","unstructured":"Moore RG, Miller MC, Disilvestro P, Landrum LM, Gajewski W, Ball JJ, Skates SJ (2011) Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol 118: 280\u2013288.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"BFbjc2016247_CR29","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ygyno.2012.04.022","volume":"126","author":"I Mutz-Dehbalaie","year":"2012","unstructured":"Mutz-Dehbalaie I, Egle D, Fessler S, Hubalek M, Fiegl H, Marth C, Widschwendter A (2012) HE4 is an independent prognostic marker in endometrial cancer patients. Gynecol Oncol 126 (2): 186\u2013191.","journal-title":"Gynecol Oncol"},{"key":"BFbjc2016247_CR30","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1365-2265.1982.tb01625.x","volume":"17","author":"CG Nilsson","year":"1982","unstructured":"Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T (1982) Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol (Oxf) 17: 529\u2013536.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"BFbjc2016247_CR31","doi-asserted-by":"publisher","first-page":"984013","DOI":"10.1155\/2010\/984013","volume":"2010","author":"T Okuda","year":"2010","unstructured":"Okuda T, Sekizawa A, Purwosunu Y, Nagatsuka M, Morioka M, Hayashi M, Okai T (2010) Genetics of endometrial cancers. Obstet Gynecol Int 2010: 984013.","journal-title":"Obstet Gynecol Int"},{"key":"BFbjc2016247_CR32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ygyno.2008.06.014","volume":"111","author":"A Orbo","year":"2008","unstructured":"Orbo A, Arnes M, Hancke C, Vereide AB, Pettersen I, Larsen K (2008) Treatment results of endometrial hyperplasia after prospective D-score classification. A follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. Gynecol Oncol 111: 68\u201373.","journal-title":"Gynecol Oncol"},{"key":"BFbjc2016247_CR33","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1111\/1471-0528.13763","volume":"123","author":"A Orbo","year":"2015","unstructured":"Orbo A, Arnes M, Vereide AB, Straume B (2015) Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens. BJOG 123: 1512\u20131519.","journal-title":"BJOG"},{"key":"BFbjc2016247_CR34","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/1471-0528.12499","volume":"121","author":"A Orbo","year":"2014","unstructured":"Orbo A, Vereide A, Arnes M, Pettersen I, Straume B (2014) Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial. BJOG 121: 477\u2013486.","journal-title":"BJOG"},{"key":"BFbjc2016247_CR35","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00432-015-2092-1","volume":"142","author":"AM Rodriguez","year":"2016","unstructured":"Rodriguez AM, Schmeler KM, Kuo YF (2016) Lack of improvement in survival rates for women under 50 with endometrial cancer, 2000-2011. J Cancer Res Clin Oncol 142: 783\u2013793.","journal-title":"J Cancer Res Clin Oncol"},{"key":"BFbjc2016247_CR36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1741-7015-8-18","volume":"8","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D. (2010) CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med 8: 18.","journal-title":"BMC Med"},{"key":"BFbjc2016247_CR37","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ejogrb.2008.02.022","volume":"139","author":"R Varma","year":"2008","unstructured":"Varma R, Soneja H, Bhatia K, Ganesan R, Rollason T, Clark TJ, Gupta JK (2008) The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia-A long-term follow-up study. Eur J Obstet Gynecol Reprod Biol 139: 169\u2013175.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"BFbjc2016247_CR38","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ygyno.2005.10.030","volume":"101","author":"AB Vereide","year":"2006","unstructured":"Vereide AB, Kaino T, Sager G, Arnes M, Orbo A (2006) Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia. Gynecol Oncol 101: 214\u2013223.","journal-title":"Gynecol Oncol"},{"key":"BFbjc2016247_CR39","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.maturitas.2006.12.004","volume":"57","author":"D Wildemeersch","year":"2007","unstructured":"Wildemeersch D, Janssens D, Pylyser K, De WN, Verbeeck G, Dhont M, Tjalma W (2007) Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up. Maturitas 57: 210\u2013213.","journal-title":"Maturitas"}],"updated-by":[{"DOI":"10.1038\/bjc.2016.330","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2016,10,6]],"date-time":"2016-10-06T00:00:00Z","timestamp":1475712000000}}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2016247.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2016247","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2016247.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T09:33:32Z","timestamp":1684402412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2016247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,18]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,9,6]]}},"alternative-id":["BFbjc2016247"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2016.247","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,18]]},"assertion":[{"value":"4 June 2016","order":1,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2016","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}